Make sure to sign up for an account today for exclusive coupons and free shipping on orders over $75!
Maximum quantity allowed is 999
Please select the quantity
CAS RN: 184475-35-2 | Product Number: G0546
Gefitinib
×
![]()
×
Purity: >98.0%(T)(HPLC)
Synonyms:
- N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine
Product Documents:
| Size | Unit Price | Philadelphia, PA | Portland, OR | Japan* | Quantity |
|---|---|---|---|---|---|
| 1G |
$83.00
|
Contact Us | Contact Us | ≥100 |
|
| 5G |
$270.00
|
Contact Us | Contact Us | 24 |
|
* Items in stock locally ship in 1-2 business days. Items from Japan stock are able to ship from a US warehouse within 2 weeks. Please contact TCI for lead times on items not in stock. Excludes regulated items and items that ship on ice.
* To send your quote request for bulk quantities, please click on the "Request Quote" button. Please note that we cannot offer bulk quantities for some products.
*TCI frequently reviews storage conditions to optimize them. Please note that the latest information on the storage temperature for the products is described on our website.
| Product Number | G0546 |
| Purity / Analysis Method | >98.0%(T)(HPLC) |
| Molecular Formula / Molecular Weight | C__2__2H__2__4ClFN__4O__3 = 446.91 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature | Refrigerated (0-10°C) |
| Condition to Avoid | Heat Sensitive |
| Packaging and Container | 1G-Glass Bottle with Plastic Insert (View image) |
| CAS RN | 184475-35-2 |
| Reaxys Registry Number | 8949523 |
| PubChem Substance ID | 468591928 |
| MDL Number | MFCD04307832 |
Specifications
| Appearance | White to Light yellow powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Nonaqueous Titration) | min. 98.0 % |
| Melting point | 194.0 to 198.0 °C |
Properties (reference)
| Melting Point | 196 °C |
| Maximum Absorption Wavelength | 332 nm |
| Solubility in water | Insoluble |
| Solubility (slightly sol. in) | Tetrahydrofuran |
GHS
| Pictogram |
|
| Signal Word | Warning |
| Hazard Statements | H302 : Harmful if swallowed. H315 : Causes skin irritation. H319 : Causes serious eye irritation. H361 : Suspected of damaging fertility or the unborn child. H373 : May cause damage to organs through prolonged or repeated exposure. H351 : Suspected of causing cancer. |
| Precautionary Statements | P501 : Dispose of contents/ container to an approved waste disposal plant. P260 : Do not breathe dust/ fume/ gas/ mist/ vapors/ spray. P270 : Do not eat, drink or smoke when using this product. P202 : Do not handle until all safety precautions have been read and understood. P201 : Obtain special instructions before use. P264 : Wash skin thoroughly after handling. P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection. P308 + P313 : IF exposed or concerned: Get medical advice/ attention. P337 + P313 : If eye irritation persists: Get medical advice/ attention. P305 + P351 + P338 : IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. P302 + P352 : IF ON SKIN: Wash with plenty of soap and water. P332 + P313 : If skin irritation occurs: Get medical advice/ attention. P362 : Take off contaminated clothing and wash before reuse. P301 + P312 + P330 : IF SWALLOWED: Call a POISON CENTER/doctor if you feel unwell. Rinse mouth. P405 : Store locked up. |
Related Laws:
| RTECS# | VA0952000 |
Transport Information:
| HS Number | 2933.99.5590 |
Application
Gefitinib: A Potent and Selective Inhibitor of EGFR Tyrosine Kinase
The epidermal growth factor receptor (EGFR), a receptor tyrosine kinase (RTK), is expressed on the cell surface of both normal and cancer cells and plays a role in the processes of cell growth and proliferation. It is reported that gefitinib (ZD1839) is a potent and selective inhibitor of EGFR tyrosine kinase (EGFRTK). In vitro, gefitinib arrests the cell cycle at G1 phase by inducing intrinsic cyclin-dependent kinase (cdk) inhibitors. Furthermore, gefitinib inhibits vascular endothelial growth factor (VEGF) production in tumor cells through inhibition of EGFR signaling, leading to suppression of angiogenesis. For your reference, [C3647] and [H1606] are key synthetic intermediates of gefitinib. (The product is for research purpose only.)
References
- Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
- Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions (a review)
- Method development and validation for the quantification of dasatinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, sorafenib and sunitinib in human plasma by liquid chromatography coupled with tandem mass spectrometry
- A simple HPLC-UV method for the simultaneous quantification of gefitinib and erlotinib in human plasma
Articles/Brochures
TCIMAIL
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.